(Q34128493)

31 July 2017

1 reference

title

Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion (English)

1 reference

31 July 2017

8

Califf RM

1 reference

31 July 2017

2

Ohman EM

1 reference

31 July 2017

Christopher B. Granger

6

object named as

Granger CB

1 reference

31 July 2017

9

Krucoff MW

1 reference

31 July 2017

1

Roe MT

1 reference

31 July 2017

Maas AC

3

1 reference

31 July 2017

Christenson RH

4

1 reference

31 July 2017

Mahaffey KW

5

1 reference

31 July 2017

Harrington RA

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

Journal of the American College of Cardiology

31 July 2017

published in

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

9-18

1 reference

The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Coronary artery patency in patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Failed coronary thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The reduction of infarct size--an idea whose time (for testing) has come

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Editorial: Assessing myocardial damage in acute infarcts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Quantitation of infarct size in man by means of plasma enzyme levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Myocardial reperfusion: a double-edged sword?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Does reperfusion injury exist in humans?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Leukocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Detection of the terminal complement complex in patient plasma following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Recognition of the importance of embolization in atherosclerotic vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Prediction of short- and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

TIMI frame count: a quantitative method of assessing coronary artery flow

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The pattern of alteration in flow velocity in the recanalized artery is related to left ventricular recovery in patients with acute infarction and successful direct balloon angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Predictive value of reactive hyperemic response on reperfusion on recovery of regional myocardial function after coronary angioplasty in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Microvascular injury in reperfused infarcted myocardium: noninvasive assessment with contrast-enhanced echoplanar magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Infarct Size After Acute Myocardial Infarction Measured by Quantitative Tomographic 99m Tc Sestamibi Imaging Predicts Subsequent Mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Estimation of Infarct Size in Man and its Relation to Prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Rapid enzyme release from acutely infarcted myocardium after early thrombolyic therapy: Washout or reperfusion damage?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

ST-segment mapping. Realistic and unrealistic expectations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thromb

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Rapid reduction of ST-segment elevation after successful direct angioplasty in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Angiographic validation of bedside markers of reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Future of reperfusion therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Adenosine for myocardial protection in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Noninvasive assessment of speed and stability of infarct-related artery reperfusion: Results of the GUSTO ST segment monitoring study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901101-3

7 January 2021

10.1016/S0735-1097(00)01101-3

Identifiers

DOI

1 reference

31 July 2017

1 reference